Hit enter to search or ESC to close
Immuneering Corporation
  • ABOUT
    • Our Approach
    • Team
    • Partnerships
    • In The News
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
  • ABOUT
    • Our Approach
    • Team
    • Partnerships
    • In The News
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
All Posts By

immun-ops2020

immun-ops2020 In Publications

Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse

Our ability to successfully intervene in disease processes is dependent on definitive diagnosis. In the case of autoimmune disease, this is particularly challenging because progression of disease is lengthy and…

Read More
immun-ops2020 In Publications

Maximizing the efficacy of angiogenesis inhibitors

The article “Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study” by de Groot et al1 was published in Journal of Clinical Oncology….

Read More
immun-ops2020 In Publications

IL-6 and ovarian cancer–letter

Clinical Cancer Research recently published an important study by Coward and colleagues (1) examining interleukin-6 as a target in ovarian cancer and last year published an investigation of the same…

Read More
immun-ops2020 In Publications

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology

Supported by the Office of International Affairs, National Cancer Institute (NCI), the “US-Japan Workshop on Immunological Biomarkers in Oncology” was held in March 2009. The workshop was related to a…

Read More
immun-ops2020 In Publications

A systematic approach to biomarker discovery; preamble to “the iSBTc-FDA taskforce on immunotherapy biomarkers”

The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration with the United States Food and Drug Administration (FDA) a programmatic look at innovative avenues for…

Read More
Previous 1 … 9 10 11
Immuneering logo
  • ABOUT
  • PLATFORM
  • PIPELINE
  • PUBLICATIONS
  • FOR INVESTORS
  • CONTACT
  • Terms of Use
  • Privacy Policy

© 2025 Immuneering Corporation.